Review

Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer

S R Lakhani

The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK

Correspondence to:
Professor Lakhani lakhani{at}icr.ac.uk

Breast cancer is a common solid malignancy in women. Over the past decade, much progress has been made in understanding the biology of breast cancer. The use of molecular and immunohistochemical techniques is providing insights that will allow us to tailor the management of patients with breast cancer. In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 mutations is discussed. J Clin Pathol: Mol Pathol(J Clin Pathol: Mol Pathol 2001;54:281–284)

Key Words: breast cancer • lobular carcinoma in situ • atypical ductal hyperplasia • CerbB2, • BRCA1 mutation • BRCA2 mutation • molecular markers

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Jongsma, A P M, Piek, J M J, Zweemer, R P, Verheijen, R H M, Klein Gebbinck, J W T, van Kamp, G J, Jacobs, I J, Shaw, P, van Diest, P J, Kenemans, P (2002). Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol. Pathol. 55: 305-309 [Abstract] [Full Text]  
• Roylance, R (2002). Methods of molecular analysis: assessing losses and gains in tumours. Mol. Pathol. 55: 25-28 [Abstract] [Full Text]